Company CVAbout Sequent Scientific Ltd 
Sequent Scientific Ltd
Small Cap
Pharmaceuticals & Drugs
Sequent Scientific Limited was originally incorporated in the name of 'P I Drugs & Pharmaceuticals Limited' on June 28, 1995. The Company name was changed from 'P I Drugs & Pharmaceuticals Limited' to 'Sequent Scientific Limited' on October 27, 2009. The Company is a leading integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (APIs and finished dosage formulations) and analytical services.
Company Coordinates
Company Details
301 Dosti Pinnacle 3rd Floor, Plot E7 Road No 22 Wagle Indl Thane Maharashtra : 400604
Registrar Details
Adroit Corporate Services Pvt Ltd, 17-20 Jaferbhoy Industrial Estate , 1st Floor, Makwana Road, Marol Naka, Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 49.92 Cr
Number of Shares
24.96 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
26-Jul-2024
24.96
49.92
101000
2
Issued under ESOP Scheme
16-Apr-2024
24.95
49.90
47500
2
Issued under ESOP Scheme
25-Apr-2022
24.94
49.89
1062500
2
Issued under ESOP Scheme
17-Dec-2019
24.84
49.67
1500000
2
Issued under ESOP Scheme
17-Dec-2019
24.84
49.67
1500000
2
Issued under ESOP Scheme
26-Mar-2019
24.69
49.37
3134800
2
ESOP
23-Sep-2016
24.37
48.75
5500000
2
Conversion of Warrants
23-Sep-2016
24.37
48.75
5500000
2
Conversion of Warrants
25-Feb-2016
22.41
44.82
179278240
2
Stock Split
25-Feb-2016
22.41
44.82
179278240
2
Stock Split
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 7 Schemes (9.58%)
FIIs
Held by 53 FIIs (6.1%)
Promoter with highest holding
Ca Harbor Investments (52.61%)
Highest Public shareholder
Quant Mutual Fund - Quant Small Cap Fund (9.04%)
Individual Investors Holdings
23.82%
Board of Directors
Management
Designation
Remuneration
Kausalya Santhanam
Non-Exec. & Independent Dir.
13.9 lacs
Sharat Narasapur
Joint Managing Director
1.94 cr
Krunal Shah
Company Sec. & Compli. Officer
0
Neeraj Bharadwaj
Non-Exec & Non-Independent Dir
0
Gregory John Andrews
Non-Exec & Non-Independent Dir
12.8 lacs
Fabian Kausche
Non-Exec & Non-Independent Dir
12.8 lacs
Kamal K Sharma
Chairman & Independent Directo
20.9 lacs
Milind Sarwate
Non-Exec. & Independent Dir.
21.9 lacs
N Rajaram
Managing Director & CEO
4.92 cr
Hari Babu Bodepudi
Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Bulk Drugs
138.14
82.38%
Bulk Drugs - Traded
18.36
10.95%
Chemicals - Traded
4.87
2.91%
Bulk Drugs
Bulk Drugs
Bulk Drugs - Traded
Bulk Drugs - Traded
Chemicals - Traded
Chemicals - Traded
Stock DNARevenue and Profits:
Net Sales:
391 Cr
(Quarterly Results - Dec 2024)
Net Profit:
3 Cr
Pharmaceuticals & Drugs
INR 3,423 Cr (Small Cap)
188.00
33
0.00%
0.61
2.86%
4.87
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
